Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | 0.00% | 0.00% | -95.41% |
Mar. 05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
Feb. 16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
Financials (USD)
Sales 2021 | 0.53 | Sales 2022 | 0.61 | Capitalization | 84.05M |
---|---|---|---|---|---|
Net income 2021 | -8M | Net income 2022 | -13M | EV / Sales 2021 | - |
Net Debt 2021 | 1.29M | Net Debt 2022 | 7.83M | EV / Sales 2022 | 151,191,556 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-5.67
x | Employees | 21 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 60.94% |
Current month | +1.18% | ||
1 month | +65.38% | ||
3 months | +330.00% | ||
6 months | -86.77% | ||
Current year | -95.41% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen LaMond
CEO | Chief Executive Officer | - | 22-10-31 |
Director of Finance/CFO | 62 | 22-10-31 | |
Satyajit Mitra
BRD | Director/Board Member | 50 | 22-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Neal
BRD | Director/Board Member | 68 | 22-10-31 |
Ho Young Huh
CHM | Chairman | 54 | 22-10-31 |
Michael Friedman
BRD | Director/Board Member | - | 23-08-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | - | +-NaN% | 12 |
24-05-14 | - | +-NaN% | 8 |
Delayed Quote OTC Markets, May 09, 2024 at 02:27 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-95.41% | 195K | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.19% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- PKBO Stock